7 recruiting, 6 completed, 4 unknown, 3 terminated. 12 Not applicable, 6 Phase 2, 4 Phase 1, 2 Phase 4.
Follow Lung Neoplasm Malignant: new trials by email Literature Review of Lung Neoplasm Malignant trials Research Report on Lung Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC Adebrelimab, Adjuvant treatment - Lung Neoplasm Malignant | Phase 2 | Not yet recruiting | Ruijin Hospital | 64 | 2026-10-20 | 2026-10-22 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| Enhanced COPD Management in Suspected Lung Cancer Patients Tailored COPD consultations - COPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis) | Not applicable | Recruiting | Ditte Krag-Hansen | 280 | 2026-03-06 | 2026-04-22 |
| Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors Low-dose radiotherapy to the intestine (ILDR), PD-1/PD-L1 monoclonal antibodies - Radiotherapy, Metastatic Solid Cancers | Phase 2 | Recruiting | Chuangzhen Chen | 48 | 2025-09-26 | 2025-11-20 |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine - Lung Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-03-20 | 2026-10-13 |
| Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules broadband collaborative pulse ablation - Lung Neoplasm Malignant, Secondary Lung Cancer | Not applicable | Unknown | Shanghai Zhongshan Hospital | 3 | 2024-07-31 | 2024-07-31 |
| Benefit of Spectral Information in Patients Suspected for Lung Cancer Spectral CT images generated by a photon counting CT scanner - Lung Neoplasm Malignant | Not applicable | Recruiting | Copenhagen University Hospital at Herlev | 1000 | 2024-05-24 | 2026-03-20 |
| Confocal Laser Endomicroscopy VERification Neelde Based Confocal Laser Endomicroscopy, Conventional diagnostic bronchoscopy - Lung Cancer, Lung Neoplasm Malignant | Not applicable | Recruiting | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) | 208 | 2023-10-18 | 2026-04-07 |
| MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer SBRT, Surgery - Lung Neoplasm Malignant | Recruiting | European Institute of Oncology | 270 | 2023-09-11 | 2024-09-23 | |
| Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer Aliya Pulsed Electric Fields (PEF) - Lung Neoplasm Malignant | Not applicable | Completed | Galvanize Therapeutics, Inc. | 30 | 2023-09-06 | 2025-08-20 |
| Self-Management Support for Lung Cancer Patients With Cachexia Self-management support nutrition and exercise intervention - Cachexia-Anorexia Syndrome, Lung Neoplasm Malignant | Not applicable | Active not recruiting | Changhua Christian Hospital | 104 | 2023-01-20 | 2026-05-13 |
| Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer sintilimab, bevacizumab - Lung Neoplasm Malignant | Not applicable | Recruiting | Ruijin Hospital | 20 | 2022-10-01 | 2024-11-19 |
| Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years Tailored nutrition and physical activity programme - Lung Neoplasm Malignant, Mesothelioma; Lung | Not applicable | Completed | University of Hull | 11 | 2022-06-20 | 2023-09-13 |
| Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy Pulmonary rehabilitation - Lung Neoplasm Malignant | Not applicable | Unknown | Asan Medical Center | 70 | 2022-06-14 | 2022-06-10 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors SAR443216 IV, SAR443216 SC - Neoplasm Malignant, Breast Cancer | Phase 1 | Terminated | Sanofi | 44 | 2021-08-16 | 2025-09-15 |
| Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy Lymphadenectomy - Lung Neoplasm Malignant | Not applicable | Unknown | Otto Wagner Hospital | 200 | 2020-10-01 | 2021-03-03 |
| Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] Atezolizumab Injection [Tecentriq] - Lung Neoplasm Malignant | Phase 4 | Completed | Chonnam National University Hospital | 100 | 2019-12-18 | 2023-02-08 |
| Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies Inspiratory muscle training - Lung Neoplasm Malignant | Not applicable | Completed | The Hong Kong Polytechnic University | 196 | 2019-11-23 | 2022-08-23 |
| Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis Prolonged glucocorticosteroid (prednisone) regimen, Short glucocorticosteroid (prednisone) regimen - Lung Neoplasm Malignant, Interstitial Lung Disease | Phase 4 | Suspended | National Institute for Tuberculosis and Lung Diseases, Poland | 85 | 2019-10-01 | 2023-02-23 |
Showing 20 of 24. Sign in to see all of them.
Lung Neoplasms (24) · Carcinoma, Non-Small-Cell Lung (6) · Motor Activity (2) · Neoplasms (2) · Thoracic Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Disease (1) · Esophageal Neoplasms (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1)
Lung Diseases (23) · Neoplasms by Site (23) · Respiratory Tract Diseases (23) · Respiratory Tract Neoplasms (23) · Neoplasms (22) · Thoracic Neoplasms (22) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Behavior (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplasms, Glandular and Epithelial (2) · Adenoma (1)
Carboplatin (2) · Pemetrexed (2) · pembrolizumab (2) · Acetaminophen (1) · Adjuvants, Pharmaceutic (1) · Bevacizumab (1) · Cetuximab (1) · Cisplatin (1) · Clinical Protocols (1) · Dexamethasone (1) · Gemcitabine (1) · Histamine Antagonists (1) · Histamine H2 Antagonists (1) · Immunotherapy, Adoptive (1) · Lymph Node Excision (1)
Merck Sharp & Dohme LLC (2) · Ruijin Hospital (2) · Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC) (1) · Asan Medical Center (1) · Blueprint Medicines Corporation (1) · Changhua Christian Hospital (1) · Chonnam National University Hospital (1) · Chuangzhen Chen (1) · Copenhagen University Hospital at Herlev (1) · Ditte Krag-Hansen (1) · European Institute of Oncology (1) · Galvanize Therapeutics, Inc. (1) · Guangdong Association of Clinical Trials (1) · National Institute for Tuberculosis and Lung Diseases, Poland (1) · Otto Wagner Hospital (1)
China (8) · United States (7) · South Korea (5) · Greece (3) · Italy (3) · Spain (3) · Taiwan (3) · Austria (2) · Chile (2) · Denmark (2) · France (2) · Poland (2) · Belgium (1) · Brazil (1) · Canada (1)
Hecheng Li, MD, PhD (2) · Alex Molassiotis (1) · Brett Bade, M.D. (1) · Cynthia Forbes, PhD (1) · In-Jae Oh, MD, PhD (1) · Jang Ho Lee, MD (1) · Jingyuan Fan, MD, PhD (1) · Jouke Annema, Prof. dr. (1) · Li Chun Chang, Master (1) · Lingxiao Liu (1) · Michael B Andersen, PhD (1) · Micheal Mueller, MD (1) · Runsen Jin, MD, PhD (1) · Stefania Volpe, MD (1)
PMID 27637832, PMID 30013197, PMID 30082870, PMID 30741408, PMID 31626055, PMID 32119883, PMID 32328828, PMID 33059998, PMID 33794808, PMID 33946039, PMID 35396177, PMID 38102575, PMID 38321811, PMID 38964802, PMID 40306134, PMID 40402333, PMID 41376917, PMID 42705861
2023 (2), P50CA196530 (1)